BioCentury | Jan 7, 2020
Financial News

BioIntervene takes on adenosine in pain, raises $30M

...targets in early-stage testing for osteoarthritis. Can-Fite BioPharma Ltd. is developing preclinical allosteric ADORA3 modulator CF602...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...structural and functional endpoints. Can-Fite BioPharma Ltd. is working on the preclinical allosteric ADORA3 modulator CF602...
BioCentury | Feb 5, 2015
Product R&D

Addex's allosterics

...α7 (CHRNA7) PAM Preclinical Alzheimer's disease (AD) Merck & Co. Inc. (NYSE:MRK) Can-Fite BioPharma Ltd. CF602...
Items per page:
1 - 3 of 3